Fezolinetant treatment is associated with a risk of drug induced liver injury. New recommendations have been introduced to minimise this risk. Liver function should be monitored before and during treatment in all patients ta…
UK Drug Safety Update · April 10, 2025
Fezolinetant (Veoza): risk of liver injury; new recommendations to minimise risk
Original title: Fezolinetant▼(Veoza): risk of liver injury; new recommendations to minimise risk
Fezolinetant carries a risk of drug-induced liver injury; new monitoring recommendations introduced for all patients.
Published by UK Drug Safety Update. HealthSignal links to the original document; the summary above is extracted from the source text.